*AAKASHAYA PATRA EXCLUSIVE STOCK FOR INVESTMENT:* 22.03.2020
LAURUS
LABS LTD
(CMP363)
(Face Value Rs.10)
ENTER LEVEL – 340 TO 350 STOPLOSS-310
TARGET 700 IN 36 MONTHS
Laurus Labs is a leading research
driven Pharmaceutical Manufacturing Company in India.Company has grown to
become one of the leading manufacturers of API for Anti-Retroviral (ARV),Oncology,
Cardiovascular, AntiDiabetics, Anti-Asthma and Gastroenterology. They are
thriving on growth opportunities in formulation manufacturing to service all
leading markets of North America,Europe and Low Middle Income Countries (LMIC).
Company is driving growth opportunities in Contract Development and
Manufacturing through their Synthesis business. Most of our manufacturing facilities
are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA etc.
Its approach remains to identify and invest ahead of time with strategic
investments in State-ofthe-Art R&D and Manufacturing Infrastructure
enabling them to become a quality supplier of high volume products. Company
filed 247 patents in which they own 98 patents.
It has an equity base of just
Rs.106.91crore that is supported by reserves of around Rs.1508.82crore.
Promoters hold 32.58% Mutual Funds hold 4.92%, FPIs & AIF hold 11.79%, FIL CAPITAL
MANAGEMENT (MARURITIUS) LTD hold 5.72%, BLUEWATER Investment Ltd hold 19.63%,
Akash Bhansali hold 1.01% while investing public hold 24.35% stake in the
company.During Q3FY20, its net profit skyrocketed 312% to Rs.73.48cr from
Rs.17.82cr in Q3FY19 on 37.8% higher sales of Rs.729.59cr fetching an EPS of
Rs.6.88. During 9MFY20, PAT zoomed 186.85% to Rs.145.12crore from Rs.50.59crore
in 9MFY19 on 20.26% higher sales of Rs.1992.58crore fetching an EPS of
Rs.13.61.
Currently, the stock trades at a
P/E of 19.6x. Company paid 15% interim dividend for FY20.
Comments
Post a Comment